Tocilizumab for the treatment of chronic antibody mediated rejection in kidney transplant recipients.

Pascale KhairallahShelief Robbins-JuarezShefali PatelVaqar ShahKatherine TomaHilda E FernandezGeoffrey K DubeKristen KingSumit Mohan Radica Z AlicicHeather MorrisRussell John Crew

Published in: Clinical transplantation (2022)

Treatment of CAAMR with tocilizumab was associated with a decrease in the rate of eGFR decline and a reduction in interstitial inflammation scores in patients with CAAMR.

Keyphrases

rheumatoid arthritis
small cell lung cancer
oxidative stress
juvenile idiopathic arthritis
rheumatoid arthritis patients
epidermal growth factor receptor
tyrosine kinase
combination therapy
systemic lupus erythematosus
drug induced